AstraZeneca plc (NYSE:AZN) – Equities researchers at Leerink Swann increased their FY2019 earnings per share estimates for shares of AstraZeneca in a report released on Thursday. Leerink Swann analyst S. Fernandez now forecasts that the company will earn $1.87 per share for the year, up from their prior estimate of $1.84. Leerink Swann has a “Market Perform” rating and a $36.00 price objective on the stock. Leerink Swann also issued estimates for AstraZeneca’s FY2020 earnings at $2.19 EPS and FY2021 earnings at $2.69 EPS.
Several other equities analysts have also issued reports on AZN. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday. Cowen reissued a “hold” rating and set a $37.00 price objective on shares of AstraZeneca in a report on Tuesday, October 17th. Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Wednesday, January 10th. Finally, BNP Paribas raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $34.48.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. AstraZeneca’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company posted $1.32 earnings per share.
Several large investors have recently bought and sold shares of AZN. Russell Investments Group Ltd. lifted its stake in shares of AstraZeneca by 198.9% during the third quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock worth $62,883,000 after buying an additional 1,235,239 shares during the period. Sector Gamma AS acquired a new stake in shares of AstraZeneca during the third quarter worth $25,094,000. Janus Henderson Group PLC lifted its stake in shares of AstraZeneca by 5,754.0% during the third quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock worth $24,617,000 after buying an additional 714,187 shares during the period. Voya Investment Management LLC lifted its stake in shares of AstraZeneca by 38.2% during the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after buying an additional 662,481 shares during the period. Finally, Point72 Asset Management L.P. lifted its stake in shares of AstraZeneca by 103.1% during the third quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after buying an additional 621,831 shares during the period. Institutional investors and hedge funds own 14.76% of the company’s stock.
WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/22/leerink-swann-equities-analysts-increase-earnings-estimates-for-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.